Stephens Kristin 4
4 · Syros Pharmaceuticals, Inc. · Filed Nov 4, 2024
Insider Transaction Report
Form 4
Stephens Kristin
Chief Development Officer
Transactions
- Tax Payment
Common Stock
2024-10-31$2.09/sh−6,104$12,757→ 36,133 total - Exercise/Conversion
Common Stock
2024-10-31+17,000→ 42,237 total - Exercise/Conversion
Restricted Stock Units
2024-10-31−17,000→ 0 total→ Common Stock (17,000 underlying)
Footnotes (4)
- [F1]Represents shares of common stock received upon vesting of a restricted stock unit award.
- [F2]Represents shares used to cover tax withholding on a restricted stock unit release.
- [F3]Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
- [F4]Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024.